Search Results - "Beslija, S" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Third consensus on medical treatment of metastatic breast cancer

Third consensus on medical treatment of metastatic breast cancer

by Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C. C., Zwierzina, H.
Published in Annals of oncology (01.11.2009)

Get full text

Journal Article

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

by Brodowicz, T, Lang, I, Kahan, Z, Greil, R, Beslija, S, Stemmer, S M, Kaufman, B, Petruzelka, L, Eniu, A, Anghel, R, Koynov, K, Vrbanec, D, Pienkowski, T, Melichar, B, Spanik, S, Ahlers, S, Messinger, D, Inbar, M J, Zielinski, C
Published in British journal of cancer (25.11.2014)

Get full text

Journal Article

Second consensus on medical treatment of metastatic breast cancer

Second consensus on medical treatment of metastatic breast cancer

by Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W.J., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C.C., Zwierzina, H.
Published in Annals of oncology (01.02.2007)

Get full text

Journal Article

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

by Zielinski, C.C, Lang, I, Inbar, M, Kahan, Z, Greil, R, Beslija, S, Stemmer, S.M, Zvirbule, Z, Steger, G.G, Melichar, B, Pienkowski, T, Sirbu, D, Petruzelka, L, Eniu, A, Nisenbaum, B, Dank, M, Anghel, R, Messinger, D, Brodowicz, T
Published in European journal of cancer (1990) (01.09.2015)

Get full text

Journal Article

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

by Lang, I, Inbar, M.J, Kahán, Z, Greil, R, Beslija, S, Stemmer, S.M, Kaufman, B, Zvirbule, Z, Steger, G.G, Messinger, D, Brodowicz, T, Zielinski, C
Published in European journal of cancer (1990) (01.11.2012)

Get full text

Journal Article

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

by Inbar, M, Lang, I, Kahán, Z, Greil, R, Beslija, S, Stemmer, S.M, Kaufman, B, Zvirbule, Z, Steger, G.G, Zielinski, C.C
Published in European journal of cancer (1990) (2011)

Get full text

Journal Article

A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

by Kose, M.F., Sufliarsky, J., Beslija, S., Saip, P., Tulunay, G., Krejcy, K., Minarik, T., Fitzthum, E., Hayden, A., Melemed, A.
Published in Gynecologic oncology (01.02.2005)

Get full text

Journal Article

5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

by Lang, I, Inbar, M, Steger, G, Greil, R, Zvirbule, Z, Beslija, S, Kahán, Z, Taskova, V, Kaufmann, B, Zielinski, C.C
Published in European journal of cancer supplements (2009)

Get full text

Journal Article

G3 A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix

G3 A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix

by Dueñas-González, A, Zarba, J.J, Alcedo, J.C, Pattarunataporn, P, Beslija, S, Patel, F, Casanova, L, Barraclough, H, Orlando, M
Published in European journal of cancer supplements (2009)

Get full text

Journal Article

115 (PB-016) - Clinicopathologic characteristics of invasive apocrine carcinoma of the breast: A single center experience from a country with limited resources

115 (PB-016) - Clinicopathologic characteristics of invasive apocrine carcinoma of the breast: A single center experience from a country with limited resources

by Imamovic, D., Bilalovic, N., Skenderi, F., Beslagic, V., Ceric, T., Hasanbegovic, B., Beslija, S., Vranic, S.
Published in European journal of cancer (1990) (01.04.2018)

Get full text

Journal Article

Clinicopathologic characteristics of invasive apocrine carcinoma of the breast: A single center experience from a country with limited resources

Clinicopathologic characteristics of invasive apocrine carcinoma of the breast: A single center experience from a country with limited resources

by Imamovic, D., Bilalovic, N., Skenderi, F., Beslagic, V., Ceric, T., Hasanbegovic, B., Beslija, S., Vranic, S.
Published in European journal of cancer (1990) (01.04.2018)

Get full text

Journal Article

3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer

3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer

by Ciuleanu, T.E, Scheithauer, W, Kurteva, G, Ocvirk, J, Koza, I, Papamichael, D, Wenczl, M, Brodowicz, T, Zielinski, C.C, Beslija, S
Published in European journal of cancer supplements (2007)

Get full text

Journal Article

Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results

Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results

by Beslija, S., Ceric, T., Hasanbegovic, B., Skenderi, F., Alidžanović, J., Kopric, D., Marjanović, I., Mekic-Abazovic, A., Sisic, I.S., Hammami, M., Pasic, A., Rasic, A., Kapisazović, E.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

200P - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results

200P - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results

by Beslija, S., Ceric, T., Hasanbegovic, B., Skenderi, F., Alidžanović, J., Kopric, D., Marjanović, I., Mekic-Abazovic, A., Sisic, I.S., Hammami, M., Pasic, A., Rasic, A., Kapisazović, E.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

200PEffects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results

200PEffects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results

by Beslija, S, Ceric, T, Hasanbegovic, B, Skenderi, F, Alidžanović, J, Kopric, D, Marjanović, I, Mekic-Abazovic, A, Sisic, I S, Hammami, M, Pasic, A, Rasic, A, Kapisazović, E
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

3068 POSTER Capecitabine + irinotecan + bevacizumab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results

3068 POSTER Capecitabine + irinotecan + bevacizumab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results

by Beslija, S, Banjin, M, Jungic, S, Obralic, N, Kecman-Malcic, G, Rakita, I, Salkic, B, Pasic, A, Tinjic, L, Ajanovic, E
Published in European journal of cancer supplements (2007)

Get full text

Journal Article

Young oncologists in the Balkans: recognized but unmet needs

Young oncologists in the Balkans: recognized but unmet needs

by Jezdic, S, Bountouroglou, N, Iordanov, V, Athanassiou, A, Radulovic, S, Kinay, M, Dediu, M, Sallaku, A, Smickoska, S, Valerianova, Z, Beslija, S
Published in Journal of B.U. ON. (01.07.2006)

Get more information

Journal Article

Clinical outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study

Clinical outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study

by Beslija, S., Ceric, T., Hasanbegovic, B., Kurtovic-Kozaric, A., Pasic, A., Mahic, N., Kalamujic, M., Cardzic, A., Alidzanovic, J., Marjanovic, I., Mekic-Abazovic, A.
Published in Annals of oncology (01.09.2017)

Get full text

Journal Article

P-189 Correlation between of expression of the enzyme topoisomerase I and p53 and result of irinotecan based therapy in patients with metastatic colorectal cancer

P-189 Correlation between of expression of the enzyme topoisomerase I and p53 and result of irinotecan based therapy in patients with metastatic colorectal cancer

by Pasic, A., Beslija, S., Djuran, A., Sefic-Pasic, I., Banjin, M., Ceric, T., Rasic, A., Hasanbegovic, B., Jalovcic, A., Kapisazovic, E.
Published in Annals of oncology (01.06.2015)

Get full text

Journal Article

Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

by Brodowicz, T, Pienkowski, T, Beslija, S, Melichar, B, Lang, I, Inbar, MJ, Anghel, R, Spanik, S, Ahlers, S, Zielinski, C
Published in Cancer research (Chicago, Ill.) (15.12.2013)

Get full text

Journal Article